Nurse Practitioner Program year 2025 Reported 2021–2025 Source: CMS Open Payments, 2026 publication

Jessica Feehan

Nurse Practitioner, Family Canton, GA Nurse Practitioner

NPI 1407290273 CMS profile 11114355

320 Hospital Rd, Canton, GA 30114

Open in the dashboard

General payments

$50,702

528 records reported · program years 2021–2025

Research payments

$0

Paid to them · None reported · program years 2021–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Jessica Feehan of Canton, GA is reported in the CMS Open Payments database as having received $50,702 across 528 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 99th percentile of Nurse Practitioner, Family profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

5 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $14,104 96
2024 General $10,299 108
2023 General $11,937 126
2022 General $10,192 129
2021 General $4,170 69

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jessica Feehan
  • Nurse Practitioner, Family median
  • Middle half of Nurse Practitioner, Family
  • National median

In program year 2025, general payments to Jessica Feehan were reported at $14,104. Among 107,232 Nurse Practitioner, Family profiles paid that year, the median was $168 and the middle half received between $53 and $521.

Show as a table
Year Jessica Feehan Nurse Practitioner, Family median Middle half National median
2019 $0 $39 $18–$91 $163
2020 $0 $32 $17–$76 $114
2021 $4,170 $124 $35–$379 $132
2022 $10,192 $141 $44–$430 $149
2023 $11,937 $154 $49–$476 $160
2024 $10,299 $165 $51–$504 $164
2025 $14,104 $168 $53–$521 $169

Breakdown

Who paid General payments · program years 2021–2025
  1. Axonics Modulation Technologies, Inc. $28,594 176 payments
  2. Bayer HealthCare Pharmaceuticals Inc. $6,607 30 payments
  3. Boston Scientific Corporation $4,524 28 payments
  4. Telix Pharmaceuticals $2,010 8 payments
  5. Sumitomo Pharma America, Inc. $881 30 payments
  6. Teleflex LLC $876 15 payments
  7. Janssen Biotech, Inc. $675 15 payments
  8. Astellas Pharma US Inc $663 23 payments
  9. AstraZeneca Pharmaceuticals LP $554 18 payments
  10. Merck Sharp & Dohme Corporation $507 21 payments
  11. Other $4,809 164 payments

Every payment, record by record

What the payments were for General payments · program years 2021–2025
  1. Food and Beverage $16,923 435 payments
  2. Travel and Lodging $14,780 70 payments
  3. Consulting Fee $10,365 10 payments
  4. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $8,380 8 payments
  5. Education $255 5 payments
Products named General payments · program years 2021–2025
  1. Axonics Urology $27,176 158 payments
  2. Nubeqa $6,607 30 payments
  3. Bulkamid $3,436 33 payments
  4. Axonics Axonics - Torque Wrench - URO $2,498 3 payments
  5. ILLUCCIX $2,010 8 payments
  6. Axonics r-SNM System $1,972 15 payments
  7. ORGOVYX $751 23 payments
  8. UroLift System $654 10 payments
  9. ERLEADA $606 14 payments
  10. GEMTESA $561 18 payments
  11. Other $8,365 305 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 23 drugs

Part D claims

1,455

Median for Nurse Practitioner: 389

Drug cost

$1,037,906

Median for Nurse Practitioner: $21,885

Branded share of claims

36.7%

Median for Nurse Practitioner: 19.6%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Erleada Apalutamide Brand 31 $454,738
Nubeqa Darolutamide Brand 12 $160,275
Orgovyx Relugolix Brand 59 $151,293
Gemtesa Vibegron Brand 181 $138,556
Myrbetriq Mirabegron Brand 99 $81,386
Methenamine Hippurate Generic 242 $18,403
Elmiron Pentosan Polysulfate Sodium Brand 12 $12,013
Estradiol Generic 121 $7,727
Tamsulosin Hcl Generic 345 $4,833
Testosterone Generic 13 $2,930

The 10 drugs with the highest cost, of 23 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 229,976 Part D prescribers listed as Nurse Practitioner; they describe a distribution and say nothing about conduct.

Billing to Medicare

Part B · data year 2024 · 55 billing codes

Paid by Medicare

$206,877

Of which drugs: $102,769

Medicare patients

636

Average age 76

Services billed

17,437

209 women, 427 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Arthritis 54%
Ischemic heart disease 41%
Cancer 37%
Diabetes 28%
Chronic kidney disease 25%
Atrial fibrillation 23%
Depression 19%
Drugs given in the clinic that this provider billed Medicare Part B for
Drug given in the clinic Where Patients Services Paid by Medicare
Injection, denosumab, 1 mg J0897 Office 19 3,420 $70,419
Leuprolide acetate (for depot suspension), 7.5 mg J9217 Office 16 120 $16,844

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Payments and prescribing

First 5 of 17 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
GEMTESA
  • Sumitomo Pharma America, Inc. $224
$224 181 —
ORGOVYX
  • Sumitomo Pharma America, Inc. $140
$140 59 —
LYNPARZA
  • AstraZeneca Pharmaceuticals LP $87
  • Merck Sharp & Dohme Corporation $49
$136 — —
PROVENGE
  • Dendreon Pharmaceuticals LLC $134
$134 — —
KEYTRUDA
  • Merck Sharp & Dohme Corporation $113
$113 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 17 in the dashboard with a free account

Records

528 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Nurse Practitioner, Family in Georgia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record